A Non-interventional Registry Study of Fluzoparib in the Treatment of Ovarian Cancer
Ovarian cancer is one of the most fatal malignant tumors that threaten women's health. The incidence rate is the third place among the female reproductive system malignant tumors, and the mortality rate ranks the first in gynecologic malignancies, the majority of patients have advanced diseases at the time of diagnosis. This observational study is to evaluate the safety and efficacy of fluzoparib in ovarian cancer patients under real conditions, especially in various subgroups of ovarian cancer patients, in order to provide information about treatment modes for ovarian cancer patients in real-world diagnosis and treatment, and preliminarily evaluate the pharmacoeconomic of fluzoparib in the treatment of ovarian cancer.
• Sign informed consent and voluntarily join the study;
• Epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer diagnosed by histology or cytology;
• ≥ 18 years old;
• The investigator determined that the patient could receive fluzoparib monotherapy or combination therapy;
• For patients with fertility, effective contraceptive methods should be used during the study period and within 90 days after the last administration of fluzoparib